Pliant Therapeutics (PLRX) Non-Current Deffered Revenue (2019 - 2020)
Pliant Therapeutics (PLRX) posted quarterly Non-Current Deffered Revenue of $581000.0 for Q4 2020, up 26.86% year-over-year from $458000.0 in Q1 2020, and up 2.83% quarter-over-quarter from $565000.0 in Q3 2020.
Pliant Therapeutics (PLRX) Non-Current Deffered Revenue (2019 - 2020) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Non-Current Deffered Revenue for 2 consecutive years, with $581000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Non-Current Deffered Revenue rose 26.86% year-over-year to $581000.0; the TTM figure through Dec 2020 stood at $581000.0 (up 26.86% YoY), while the FY2020 annual figure was $581000.0, up 26.86% from the prior year.
- Non-Current Deffered Revenue advanced to $581000.0 in Q4 2020 per PLRX's latest filing, from $565000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $581000.0 in Q4 2020 and bottomed at $458000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 581,000.00 |
| Sep 30, 2020 | 565,000.00 |
| Jun 30, 2020 | 540,000.00 |
| Dec 31, 2019 | 458,000.00 |